Study results indicate abnormalities in the vestibular cortical network may help researchers understand the underlying mechanisms of vestibular migraine.
Functional connectivity (FC) between regions with a decline in gray matter (GM) volume is altered in patients with vestibular migraine (VM), according to study results published in Frontiers in Neuroscience. Findings suggest that abnormalities in the vestibular cortical network may be useful for understanding the underlying mechanisms of VM, authors wrote.
Although the exact pathophysiology of VM is not fully understood, it is the most common neurological cause of vertigo and affects between 1% and 2.7% of the adult population.
“Previous studies suggest that recurring migraine and vertigo attacks over time may lead to selective damage to several brain regions involved in pain and visual and vestibular processing,” researchers explained. “Furthermore, VM may have cumulative effects on brain structure, because some alterations may be associated with a longer disease duration and increased migraine frequency.”
Using multimodal imaging approaches by combining voxel-based morphometry (VBM) and resting state FC analyses, investigators sought to identify changes in GM volume and abnormal FC in patients with VM during the interictal period.
A total of 30 patients with VM (24 without aura, 6 with aura) were recruited from an outpatient center in China between January 2016 and October 2020. All participants did not take medications for at least 3 days prior to their functional MRI (fMRI) scan.
All patients were also required to be attack-free during the experiment and underwent MRIs in the following 3 to 7 days after a VM attack. Thirty healthy controls (HCs) were included in the final analyses.
Researchers found:
“Our present data demonstrate changes in FC in resting-state networks of brain regions with structural alterations,” the authors noted.
The main finding of a significant loss of GM volume in the PIVC among those with VM is in line with previous studies; this region “is recognized as the core region of the vestibular cortex in humans,” they continued.
As impaired GM volume in the PIVC was negatively correlated with the DHI score, this relationship underscores that recurring long-term headache and vertigo attacks have a cumulative effect on GM volume. Abnormal GM volume may thus contribute to dysfunction in information processing, supporting the notion that impaired GM volume is linked with the pathophysiology of VM.
In addition, “it is possible to speculate that the GM volume reductions of the PIVC led to a systems-level alteration in FC,” authors wrote, although more studies are needed to answer this question.
The relatively small sample size and lack of a comparative study among migraine subtypes (aura vs no aura) mark limitations to the current analysis. The cross-sectional nature of the study also precludes any causal conclusions from being drawn.
Reference
Zhe X, Zhang X, Chen L, et al. Altered gray matter and functional connectivity in patients with vestibular migraine. Front Neurosci. Published online July 8, 2021. doi:10.3389/fnins.2021.683802
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen